Insider Trading April 3, 2026

CoreWeave CEO Completes $34.9 Million Share Sales; Company Reports Technical and Financing Milestones

Michael Intrator sold 418,722 Class A shares under a 10b5-1 plan as CoreWeave posts MLPerf gains and closes an $8.5 billion delayed draw facility

By Hana Yamamoto CRWV
CoreWeave CEO Completes $34.9 Million Share Sales; Company Reports Technical and Financing Milestones
CRWV

CoreWeave CEO and President Michael N. Intrator, a director and 10% owner, sold 418,722 shares of Class A Common Stock on April 1, 2026, for approximately $34.9 million under a Rule 10b5-1 plan. The company also disclosed benchmark performance gains on Nvidia GB200 and GB300 systems and the closing of an $8.5 billion delayed draw term loan facility. Analysts maintained mixed ratings and price targets in response to the company’s financing and operational developments.

Key Points

  • CoreWeave CEO Michael N. Intrator sold 418,722 Class A shares on April 1, 2026, generating about $34.9 million under a Rule 10b5-1 plan.
  • The company reported MLPerf Inference v6.0 benchmark gains using Nvidia GB200 and GB300 systems, with the GB300 NVL72 delivering results described as twice as effective versus prior configurations.
  • CoreWeave closed an $8.5 billion delayed draw term loan facility that was oversubscribed and included global financing institutions; analysts maintained a range of ratings and price targets thereafter.

CoreWeave, Inc. reported that Michael N. Intrator, the company’s Chief Executive Officer and President - who also serves as a director and holds a 10% ownership stake - sold a total of 418,722 shares of Class A Common Stock on April 1, 2026. The aggregate proceeds from those sales were approximately $34.9 million, with transaction prices ranging from $77.4778 to $80.164 per share.

The sales were carried out pursuant to a Rule 10b5-1 trading plan that Intrator adopted on November 20, 2025. The company said the trades were executed at several price points: $77.4778, $78.4873, $79.3581 and $80.164 per share.

Company filings provide a breakdown of the trades. Intrator sold shares directly as follows: 209,22 shares at a weighted average price of $77.478, 95,609 shares at a weighted average price of $78.4873, 77,433 shares at $79.3581 and 6,036 shares at $80.164. Additional sales were completed indirectly through entities affiliated with Intrator.

Omnadora Capital LLC disposed of 11,266 shares at $77.478, 51,482 shares at $78.4873, 41,695 shares at $79.3581 and 3,250 shares at $80.164. PMI 2024 F&F GRAT sold 13,504 shares at $77.478, 61,708 shares at $78.4873, 49,976 shares at $79.3581 and 3,896 shares at $80.164. The Silver Thimble Resulting Trust sold 758 shares at $77.4778, 3,461 shares at $78.4873, 2,803 shares at $79.3581 and 218 shares at $80.1634.

On the same date, Intrator also reported conversions of Class B Common Stock into Class A Common Stock completed indirectly through those same entities. The conversion totals were 107,693 shares through Omnadora Capital LLC, 129,084 shares through PMI 2024 F&F GRAT and 7,240 shares through Silver Thimble Resulting Trust. After the sales and conversions, Intrator directly owns 5,528,900 shares of Class A Common Stock.

Market movement following the disclosures pushed the stock to $82.24, a level the company noted reflects a near 10% gain over the prior week and a 72% return over the last 12 months.


Separately, CoreWeave highlighted technical benchmark results for its Nvidia-based systems. The company reported significant gains on the MLPerf Inference v6.0 benchmark suite using GB200 and GB300 systems. CoreWeave said the GB300 NVL72 system produced results that were twice as effective as the company’s previous configurations on that suite.

CoreWeave also announced the closing of an $8.5 billion delayed draw term loan facility. The company described the facility as oversubscribed and said it included participation from global financing institutions. The filing notes this is the company’s fourth such facility.


Analysts responded to these developments with largely supportive ratings but varied price targets. Citizens reiterated a Market Outperform rating and a $180.00 price target, citing the strength of CoreWeave’s debt financing. Evercore ISI maintained an Outperform rating with a $120.00 price target, reflecting confidence in the company’s financing activities. Stifel kept a Hold rating with a $110.00 price target, characterizing CoreWeave’s efforts to position itself as an investment-grade infrastructure company. Barclays maintained an Equalweight rating and a $90.00 price target, noting concerns tied to a partnership change for a Texas data center project. That project with Poolside is seeking a new partner after strategic differences led to a split with CoreWeave.

This set of disclosures - insider sales, share conversions, technical benchmark claims and a large financing - together compose the latest publicly reported developments for CoreWeave. The company’s filings provide the transaction detail and the analyst commentary reflects how market observers are weighing the financing and operational updates.

Risks

  • Insider sales and share conversions could be viewed as liquidity events that market participants may interpret in different ways - this may impact investor sentiment and equity trading in the technology and infrastructure sectors.
  • A partnership change for a Texas data center project and the search for a new partner after a split with Poolside introduces project-level uncertainty in CoreWeave’s data center and infrastructure operations.
  • Reliance on large-scale financing, even when oversubscribed, may affect the company’s capital structure and attracts scrutiny from debt and equity market participants in financial markets.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026